Vertex Pharma's most recent trend suggests a bearish bias. One trading opportunity on Vertex Pharma is a Bear Call Spread using a strike $215.00 short call and a strike $225.00 long call offers a potential 19.05% return on risk over the next 20 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $215.00 by expiration. The full premium credit of $1.60 would be kept by the premium seller. The risk of $8.40 would be incurred if the stock rose above the $225.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Vertex Pharma is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Vertex Pharma is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Vertex Pharma
Vertex Pharmaceuticals Inc (VRTX) Q3 2020 Earnings Call Transcript
Fri, 30 Oct 2020 09:01:33 +0000
This is Michael Partridge, Senior Vice President of Investor Relations for Vertex. Making prepared remarks on the call tonight, we have Dr. Reshma Kewalramani, Vertex's CEO and President; Stuart Arbuckle, Chief Commercial Officer; and Charlie Wagner, Chief Financial Officer; Dr. David Altshuler, Chief Scientific Officer, will join the Q&A portion of the call following the prepared remarks.
Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings and Revenue Estimates
Thu, 29 Oct 2020 21:35:09 +0000
Vertex (VRTX) delivered earnings and revenue surprises of 10.46% and 3.38%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: Vertex Pharmaceuticals Q3 Earnings
Thu, 29 Oct 2020 20:52:11 +0000
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) decreased 1.4% in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share increased 114.63% over the past year to $2.64, which beat the estimate of $2.32.Revenue of $1,538,000,000 higher by 61.92% year over year, which beat the estimate of $1,470,000,000.Guidance Vertex Pharmaceuticals hasn't issued any earnings guidance for the time being.The upcoming fiscal year's revenue expected to be between $6,000,000,000 and $6,200,000,000.How To Listen To The Conference Call Date: Oct 29, 2020View more earnings on VRTXTime: 04:30 PMET Webcast URL: https://event.webcasts.com/starthere.jsp?ei=1392359&tp_key=78b8fb16aaRecent Stock Performance Company's 52-week high was at $306.0852-week low: $192.32Price action over last quarter: down 23.89%Company Description Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex's pipeline also includes therapies for cancer, pain, inflammatory diseases, influenza, and other rare diseases.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For October 29, 2020 * Benzinga's Top Upgrades, Downgrades For October 28, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Vertex Reports Third-Quarter 2020 Financial Results
Thu, 29 Oct 2020 20:01:00 +0000
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2020 and revised upward its full-year 2020 financial guidance for product revenues.
Vertex Pharmaceuticals, Inc.to Host Earnings Call
Thu, 29 Oct 2020 18:30:00 +0000
NEW YORK, NY / ACCESSWIRE / October 29, 2020 / Vertex Pharmaceuticals, Inc.
Also on Market Tamer…
Follow Us on Facebook